A Study to Evaluate Whether Probiotics for Gut Microbiome Will Target Cancer Immune Microenvironment in Breast and Lung Cancer

Overview

About this study

The purpose of this study is to evaluate whether engineering gut microbiome using probiotics will alter host immunological response to breast and lung cancers.

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Males or females ≥ 18 years of age.
  • Patients with operable breast or lung cancer with tumors ≥ 1cm (according to imaging) prior to surgery not requiring neoadjuvant therapy.
  • Histologically confirmed adenocarcinoma of the breast operable stage I-III or histologically confirmed carcinoma of the lung operable stage I-III will be enrolled prior to their definitive surgery.
  • Patients must have adequate organ function, not receive systemic neoadjuvant therapy, and be willing to provide tissue, blood, and stool samples for research study.
  • Patients must not have taken any probiotics in the past 30 days prior to the enrollment.

Exclusion Criteria:

  • Patients < 18 years of age.
  • Patients with autoimmune disease, immune deficiency such as HIV, irritable bowel, known diverticulosis, and other serious GI conditions at treating physician’s discretion will be excluded.

Eligibility last updated 1/12/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Saranya Chumsri, M.D.

Contact us for the latest status

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions